Lion Street Advisors LLC Has $894,000 Stock Position in Johnson & Johnson $JNJ

Lion Street Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,850 shares of the company’s stock after selling 1,351 shares during the period. Lion Street Advisors LLC’s holdings in Johnson & Johnson were worth $894,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. GFG Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $190.96 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $179.68 and a 200 day simple moving average of $164.34. The stock has a market capitalization of $459.90 billion, a PE ratio of 18.43, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion during the quarter. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on JNJ shares. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.